
Sign up to save your podcasts
Or


What is the Role of Artificial Intelligence in Drug Development and Drug Discovery?
⭐ In this episode, we talk about:
Today’s speaker is Marco Schmidt, CSO of Biotx.ai
Marco had an exceptional academic career. He won the best PhD of the year award in Chemistry in his home country Germany and then went on to do a Post-Doc at the University of Cambridge.
⭐ EPISODE Links:
Marco Schmidt on Linkedin
Youtube
📖 Quotes:
(24:45) “Eroom's law is the observation that drug discovery is becoming slower and more expensive over time”
(56:05) “We need more data”
(58:13) “Biobanks provide the infrastructure that we really need in the future”
(01:16:39) “Prediction Models of Type 2 Diabetes Have 99% Accuracy”
(01:17:50) “There is no longevity gene. There are shortevity genes.”
(01:53:45) “We are living in fantastic times”
⏰ Timestamps:
(00:00) Kick Off and Intro
(06:15) Deep Mind’s Alphafold
(07:06) Background to Marco Schmidt and Biotx.ai
(12:00) Business Model in AI for Drug Development – from Service Provider to Developer
(13:15) Basic Definition of Drug Discovery and Drug Development for the Listeners of the Episode
(17:20) For Retail Investors who have an eye on investing in public drug development companies: What is a Ligand?
(20:09) Why is Drug Discovery Expensive and Lengthy?
(23:30) Success and Failure Rate in Drug Development
(24:30) What is erooms Law?
(27:25) What is the right place for innovation? Startups or Big Corporations?
(30:00) The Value Chain in the Pharma Industry – From Research to Marketed Products.
(34:00) Investing in Life Science Companies
(50:15) Why is Artificial Intelligence an Attractive Area?
Speaker and Company
(55:00) The State of AI in Drug Development and Drug Discovery – What is Science and What is Still Fiction.
(58:00) Accessibility of Data – Is this the bottleneck in Artificial Intelligence Based Drug Discovery?
(01:10:00) What would change in Drug Development if scientists could access healthy population data?
(01:12:30) Prediction Models for Cancer, Alzheimer, and other diseases
(01:16:00) Understanding the progression of diseases and the role lifestyle plays in AI
(01:19:00) How does GDPR limit the development of AI in Drug Discovery
(01:24:00) Data Curation in AI
(01:28:45) Is Capital a Limiting Factor?
(01:34:26) The Human Genome and AI
(01:40:00) Is it possible to simulate the entire drug development process from lab to market?
(01:46:00) Service Offerings of biotx.ai
(01:51:30) How can AI help select the right patients?
(01:59:00) Synthetic clinical trials
(02:01:00) The Role of Excel in Machine Learning
📚 Book Mentions:
Drug Discovery and Drug Development
The Power Law
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
Do you understand the dynamics of the stock market? Here is an episode with Brian Feroldi, Writer at the Motley Fool, on his new book “Why the stock market goes up?”
We are talking about
⭐ The Global Problem With Financial Literacy
⭐ Why Did Brian Feroldi Write a Book About Investing for Beginners?
⭐ Why Does the Market Crash from Time to Time?
⭐ Cost Averaging and Index Investing – A Powerful Tool for People who don’t have time to diligently follow the market
⭐ What was Brian’s Biggest Investment Mistake?
A basic understanding of the stock market is mandatory for every deep tech entrepreneur, business angel, and venture capitalist. A stock market is a place where companies can get more liquidity for scaling their business and provides an exit for early investors.
Brian Feroldi describes the mechanics of the stock market in his latest book: Why does the stock market go up? I enjoyed his unique way of explaining complex economic situations in easy-to-understand layman’s terms.
Brian Feroldi is a financial educator, YouTuber, and author. Since college, he has been intensely interested in money, personal finance, and investing.
⭐ EPISODE Links:
Brian Feroldi on Youtube
Youtube Video
📖 Quotes:
(05:31) "A lack of financial literacy is a global phenomenon"
(14:50) "...it took me about 18 months to write it. ... I think we needed a book that explains in plain English what the stock market is - for beginners."
(16:11) "If you look back on stock market history - it is very clear: Every ten years ... or so ... things go to hell!"
(33:00) "Only Business Profits drive the Stock Market in any given direction"
(43:53) "Investing in an Index Fund is totally fine for 99% of investors because they have no interest in reading SEC filings or doing research."
(01:08:00) "Think Long-Term"
⏰ Timestamps:
(00:00) Introduction
(01:52) Why Deep tech Entrepreneurs Need a Basic Understanding of the Stock Market.
(04:00) Brian Feroldi's studio
(05:17) The Problem With Financial Literacy
(06:35) How Brian got Into Investing?
(08:00) The Motley Fool
(10:05) Why Did Brian Feroldi Write a Book About Investing for Beginners?
(15:00) Reflecting on the Tech Market Correction in 2022 and Other Stock Market Crashes
(19:19) The 2000 and 2008 Crash Experience
(23:20) Why Does the Market Crash from Time to Time?
(27:50) Crowd Mentality, Market Timing, and Contrarian Investing
(32:55) The 3 Major Forces That Drive the Stock Market Up
(36:55) Why Should People Invest When Fear, Uncertainty, And Doubt are on the Market?
(39:32) What were your biggest questions when you started investing?
(43:25) Warren Buffetts S&P500 ETF Strategy for People who don't have time for market research
(45:23) Cost Averaging and Index Investing – A Powerful Tool for People who don't have time to diligently follow the Market
(48:00) What is Compounding?
(51:11) What is the Magnitude of Stock Market Fluctuations
(55:05) Brian Feroldi's on Cathie Wood's Ark Innovation Fund
(01:00:00) What was Brian's Biggest Investment Mistake?
(01:04:00) Brian's Preferred Investment Style – Warren Buffett, Ray Dalio, or Cathie Wood?
📚 Book Mentions:
“Rich Dad, Poor Dad.” Link: https://amzn.to/3zuC0wr
“One Up on Wallstreet” Link: https://amzn.to/3zxSkwv
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
Where are the Big Life Science Hubs in the United States?
Here is an in-depth overview of Life Science In Georgia with many essential Key Facts and exciting stories from the beautiful state. My guest in this episode is E Jane Caraway, Director of Life Science at the Georgia Department of Economic Development.
⭐We are talking about
⭐About Georgia
The state of Georgia is a dynamic hub for life sciences with more than 2,000 organizations. We have the resources to assist you in getting ideas researched, tested, commercialized, produced, and delivered quickly to most anywhere in the world. New and existing companies have access to a highly educated workforce, renowned research institutions, cutting-edge technological resources, and access to the global marketplace via a robust infrastructure. Georgia’s pro-business climate, combined with a culture of collaboration and innovation, has fostered growth across all sectors of life sciences.
⭐ EPISODE Links:
E Jane Caraway: EJane Caraway, a passionate advocate for company success and community growth, has been with the Georgia Department of Economic Development for 13years. Since 2017 she has served as the Director of Life Sciences, and recently worked on projects with companies like Boehringer Ingelheim, Boston Scientific and IC Biomedical, just to name a few.
Youtube
🎤 Quotes:
(09:41) “Georgia has the second largest film industry in the world, after Canada and before Hollywood”
(18:51) “The Soccer World Championship 2026 will be in the United States”
(22:41) “Facebook has worked with local partnerships and entrepreneurs to build their own solar fields to supply energy to their facilities in Georgia”
(28:41) "Georgia had a 150% growth in the Life Science Industry in 2021"
🕛 Timestamps:
(00:00) Intro
(03:00) Recap of the #bio2022 in San Diego
(05:35) Background EJane Caraway and Life Sciences in Georgia
(08:00) What do Life Science, Canyons, Vineyards, Vampires, She-Hulk, King of Queens, and Zombies have in common?
(10:00) The Film Industry in Georgia
(15:30) Sports in Georgia – Baseball, Soccer, Football, Golf, Pickleball
(21:30) Georgia’s Leading Industries – Coca Cola, Delta Airlines, NCR, Facebook, Boehringer Ingelheim, HomeDepot, Aflac, UPS
(23:45) Boehringer Ingelheim in Atlanta, Georgia and Vienna, Austria
(28:55) Life Science in Georgia has seen a 150% Growth Rate in 2022
(33:00) The Positive Impact Life Science Companies Make in the Community – The Takeda Story
(36:12) The Boston Scientific, AMRI and Gulf Stream – Ebola Story
(41:21) Science in Georgia
(44:30) Starting a Company in Georgia as an Immigrant Entrepreneur – How is the Workforce, Labspace, and Funding Situation in Georgia?
(51:30) The Georgia Department of Economic Development is a One Stop Shop for Life Science Entrepreneurs
(53:12) Success Stories from Life Science Companies in Georgia
(57:14) Why should life science entrepreneurs start their businesses in Georgia?
(59:25) Support the State of Georgia offers to entrepreneurs
(01:02:39) Are you interested in starting your business in Georgia? Here is how!
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
What are the opportunities for Biotechs in the Chinese Market? Get answers to this question in this podcast with the BFC Group.
⭐We are talking about
The BFC Group
The Capital Market Landscape in China
Deal Structuring in China
Clinical Strategies for China
Why Affordability and Accessibility of new drugs matter in China
⭐About BFC Group:
BFC Group is a China-based investment banking firm with a focus on healthcare M&A, licensing, and financing. We work with leading healthcare companies in the US, Europe, and Asia. With first-hand operational experience in both the US and China, we have a deep understanding of the challenges our clients face when establishing or expanding their companies’ presence outside of their home market.
⭐ EPISODE Links:
Jia En Chin
Thijs Spoor
Shirley Lu:
BFC Group:
Youtube Presentation best viewed on Youtube
🎤 Quotes:
(26:04) “China is now the second largest pharma market in the world, Japan being third”
(31:11) “Many of our clients are still in Clinical Phase I, when they come to China”
(33:29) “The China Market really rewards innovation in antibiotic research.”
(48:30) “China takes care to make therapeutics accessible and affordable for the population”
(51:24) “China's growing middle class wants to improve their quality of life.”
(59:45) “Finding the right partner for a Go-To-China-Strategy is key to success. Otherwise, it can become very costly and might damage the asset.”
(01:00:38) "... you want a personal connection, you want to educate and not sell..."
(01:16:30) “In Q1/2022 18 new drugs were approved in China, 12 of them came from The West.”
🕛 Timestamps:
(00:00) Introductions
(13:00) BFC Group Introduction to the Chinese Market
(15:45) Capital Market Landscape in China
(18:30) China Investment and Financing Trend
(21:43) Licensing Deal Trends in China
(25:00) Opportunities for Biotechs in China
(25:45) The biggest Pharma Markets and Innovators
(30:00) Deal-Focus of Chinese Pharma Companies
(32:00) The Therapeutic Focus in China in 2022
(33:41) Antibiotics Research in China
(36:40) The Major Player in Infectious Diseases and Cancer on the Chinese Market
(38:00) Market Potential in China for Chronic Diseases
(39:55) The KBP Business Case
(40:48) Patent Strategies for the Chinese Market
(44:24) Important Points for Preparing a Market Entry in China
(48:00) Price Dynamics and Reimbursement in China
(49:30) Why Affordability and Accessibility Matters in China
(50:30) The Necessary Data Packages for Market Entry in China
(53:00) Clinical Strategies for Market Entry in China
(56:30) Is a multi-center approach across several markets feasible in later-stage clinical trials?
(01:01:30) Similarities and Differences in Culture, Communication
(01:08:15) The Right approach for a Go-To-China Strategy
(01:13:22) The Availability of Capital on Private and Public Markets for Foreign Companies
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
Fundraising in Israel and the United States – In this episode, I have a conversation with Tuvik Beker, CEO of Pangea Biomed, who has started, developed, and exited companies in the United States and Israel. Now he is developing Pangea Biomed to start the next revolution in precision oncology.
Tuvik Beker is a seasoned entrepreneur, an experienced executive, and a strong technical leader who spent the last twenty years building, scaling, and leading companies in the healthcare, financial, and aerospace domains.
Founded in 2018, Pangea Biomed is an Israeli biotech startup redefining cancer care. The company developed ENLIGHT – the world's most advanced multi-cancer, multi-therapy response predictor. By combining machine learning and deep RNA analysis, the company is mapping tumor molecular signatures to dynamically and adaptively personalize cancer care for a healthier world.
⭐In this episode, we talk about:
The Startup Ecosystem in Israel
Fundraising in the United States from 2000 to 2022
3 Success Secrets to Fundraising in the US
Precision Oncology
The Enlight Technology
Youtube
🎤 Quotes:
(11:58) “Nothing is Impossible"
(31:05) “The Abundance of Capital is one important factor. Another one is, how the area around Stanford University welcomes immigration and foreign innovation."
(35:33) “Many US Investors invest only in US companies”
(40:26) “"If you want to succeed in fundraising, you need to have a wide funnel. You need to start talking to many, many venture capitalists to close a round."
(44:21) “Be mentally ready to have 100 meetings or more to get the initial cheque.”
(50:30) "The most important thing to bear in mind is building honest relationships with venture capitalists."
(01:14:06) “Pangeas approach focuses on harnessing these expression abnormalities in order to attack cancer cells and spare normal healthy cells.”
🕛 Timestamps:
(00:00) Opening
(05:32) The Origin of Pangea Biomed
(07:45) The Startup Ecosystem in Israel
(10:16) Conversation Culture in Israeli Schools
(12:05) IDF: “Nothing is Impossible”
(13:55) Compulsory Military Service Contributes to the Success of the Startup Eco-System
(19:03) Founding a Start Up in Israel
(23:15) The Big StartUp Hubs in Israel
(25:16) StartUp Life in Tel Aviv
(28:00) StartUp Life in Palo Alto & Stanford
(30:52) The Role of Silicon Valley in Entrepreneurship and Venture Capital
(33:52) Fundraising in the United States from 2000 to 2022
(40:00) The 3 Success Secrets to Fundraising in the United States
(56:00) Search Strategies During Fundraising in 2022 – signal.nfx.com
(01:01:00) Recommendations when pitching US Investors
(01:07:52) Pangea’s Solution in Precision Oncology
(01:15:44) The Enlight Technology
(01:20:30) How Pangea Helps to Find the Right Patient Population for Clinical Trials in Oncology
(01:25:00) Pangea’s Collaboration Network
(01:34:00) Enlight – Matchmaking between Patient and the right drugs
(01:36:00) Pangea’s Business Model
(01:40:00) Pangea’s Development Team
(01:42:20) What is the next development step?
(01:44:58) Advice to first-time founders
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
In this episode, Tobias Silberzahn, McKinsey talks about biohacking 101 – habits that make a difference, digital health eco-system, and much more…
Tobias Silberzahn is a trained biochemist and immunologist and works as a Partner in McKinsey's Berlin office, where he is a member of the Healthcare and Innovation Practice. His work focuses on healthcare innovation, health tech business-building, and digital transformation.
Tobias leads the global Health Tech Network, a community of 1500+ health tech CEOs/Founders, where he hosts the quarterly Health Tech CEO Roundtable. As part of his work, Tobias also hosts the MedTech R&D Industry Roundtable and publishes the "eHealth Monitor Germany," an annual book about the digitization of the German health system.
Within McKinsey, Tobias leads the Health & Wellbeing program for employees, focused on sleep, nutrition, stress management, and fitness, that was recently awarded the Brandon Hall HCM Excellence Award in Gold.
McKinsey is a global management consulting firm committed to helping organizations accelerate sustainable and inclusive growth. McKinsey works with clients across the private, public, and social sectors to solve complex problems and create positive change for all their stakeholders. It combines bold strategies and transformative technologies to help organizations innovate more sustainably, achieve lasting gains in performance, and build workforces that will thrive for this generation and the next
Youtube (Links to articles discussed in the podcast are in the description to the Youtube Video)
We were talking about:
⭐ The European Health Care System
⭐ Biohacking 101
⭐ The Healthtech Startup Eco System
⭐Small Habits – Big Changes
⭐ The 4 Pillars of Health and Wellbeing
🕛 Timestamps:
(00:00) Introduction
(05:30) The Situation of Mental Health, Health & Well-Being in Europe
(10:10) The Role of Sleep For Health & Wellbeing
(14:00) Mobility & Movement
(18:43) Why Nutrition Matters
(23:24) Healthcare and Cancer
(29:46) Digital Tools for Managing Micro Habits
(36:30) How Important are Digital Health Solutions for the Future Healthcare System – a Journey through State of the Art System
(43:40) How Can Digital Tools Increase the Level of Health Literacy in Society?
(49:30) How to Bring Health Education to all People –Solutions by McKinsey
(58:54) How to Measure the Benefits of Happiness at Companies
(01:02:38) The Cost of health deficits for the European Society
(01:08:30) The Role Different Stakeholders Play to Improve the Healthcare System
(01:16:30) Tobias Silberzahn’s Global Healthtech Network – A Community of 1,500+ Healthtech CEOs and Founders
(01:20:30) The Future of Healthcare is Full Of Opportunities
(01:21:35) The Role of Precision Medicine
Do you want to support the podcast?
Join the LSG2G Community: https://lsg2g.substack.com/subscribe
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
What are decentralized clinical trials?
What are the benefits of decentralized clinical trials?
Why are decentralized clinical trials the way of the future?
Emily Mitchell, Executive Director of ICON’s DCT team, discusses the benefits of these trials and what needs to be considered to ensure these benefits are realized.
Emily Mitchell has over 15 years of experience working in the CRO industry in Data Management, Project Management, and Clinical Operations. During her tenure at ICON, Emily partnered with an actigraphy vendor to run a pilot study with employees on the wear compliance and comparison of a medical grade activity tracker to a commercial grade version.
Before the pandemic, Emily helped set up and support the first fully decentralized trial at ICON. She has continued to present at various conferences around the best practices for decentralized studies, ensuring minimized patient and site burden while optimizing data capture. Emily is an active member of the Society of Clinical Data Management (SCDM) and has presented about decentralized trials at numerous conferences.
ICON is the only CRO to offer all services (without the need to contract third-party services or technology) and deliver end-to-end integrated decentralized clinical trial solutions.
ICON supported the delivery of the first decentralized clinical trial that has had positive published results in a medical journal – Nature Medicine
We are talking about
⭐ Decentralized clinical trials
⭐How they benefit patients
⭐The impact on budgeting
⭐Successful deployment of clinical trials an
⭐ Much, much more
Youtube
🕛 Timestamps:
(00:00) Intro
(03:30) Kick off with Summer Weather
(06:30) What are Decentralized Clinical Trials (DCT)
(07:30) Benefits of DCT
(08:45) Real-Life Example for a DCT from ICON Plc
(11:48) What was the Motivation to Develop the DCT Model before the Pandemic?
(14:30) Logistics in Clinical Trials
(16:20) Managing DCT
(17:45) Patient Response to DCT
(18:35) Benefits of DCT in Increasing Diversity in Patients Population
(22:30) More Diversity in Patient Population Equals More Valuable Data
(26:00) The Role of Social Media in Patient Recruitment
(27:22) Data Management in Decentralized Clinical Trials
(29:25) Improvement in Data Collection With AI/ML, Tablets, And Wearables
(31:07) DCT and associated cost
(34:08) Which Indications are suitable for DCT?
(37:30) How do decentralized clinical trials impact the duration of a trial?
(40:15) How long does the planning phase in a DCT model take?
(43:30) ICON’s Partnership Model
(47:13) The Demographics of Social Media as a Recruitment Tool for Clinical Trials
(50:10) Patient Experience in DCT
(52:57) How to Keep Patients Motivated Through a DCT
(56:00) Data Collection by Patients
(57:40) Long-term follow-ups in the DCT Model
(01:00:55) Patient Empowerment in Decentralized Clinical Trials
(01:02:45) Do You Want to Evaluate Decentralized Clinical Trials? Here are the next steps ([email protected])
Do you want to support the podcast?
Join the LSG2G Community: https://lsg2g.substack.com/subscribe
Send us Fan Mail
The LSG2G PartnersSupport the show
Join the Podcast Newsletter: Link
Your Next Move: Link
What is the best approach to starting a novel deep tech life science company?
In this episode, I am talking with Samatha Dale Strasser, CSO, and co-founder of Pepper Bio, about her academic career at the University of Cambridge and MIT and the process of starting Pepper Bio.
Backed by VC firm NFX, Pepper Bio uses proprietary lab methods and computational abilities to unlock a new level of sophistication in drug discovery.
Called the "Google Maps for drug discovery" Pepper Bio helps partners find the safest, fastest route to new, effective drugs in clinical trials by analyzing transomics data.
So far, the company has already identified applications of its technology for rare diseases in oncology, neurology, and inflammatory.
Samantha Dale Strasser, PhD, is CSO and co-founder of Pepper Bio. Samantha co-founded Pepper Bio based on foundational work she pioneered during her PhD studies at MIT. Her development of the first trans-omic machine learning platform revolutionizes how we discover drugs and treat disease. This approach has already identified and validated previously unseen insights in inflammatory diseases and undruggable cancers. She paved the way to Pepper’s first commercial partner, eager to apply this approach to central nervous system diseases.
We are talking about:
⭐The Eco-Systems in Boston
⭐ The Importance of Aligning Vision – Mission – Goals – Actions
⭐ Challenges in Drug Development
⭐ Fundraising strategies for the United States
⭐The Story Behind Pepper Bio
⭐ And Much, Much more
Youtube
🕛 Timestamps:
(00:00) Introduction Pepper Bio and Samantha Dale Strasser
(02:30) Start of the recording
(03:00) Heatwaves, Paintings, and the Sky Above Boston
(05:00) Culture in Boston/Cambridge and Cambridge, UK – MIT and the University of Cambridge
(16:08) Samantha's Motivation to Start Pepper Bio
(19:20) The Startup Eco-System in Boston, Massachusetts
(21:27) The 3 Critical Key Success Factors of the Deep Tech Eco-System in Boston
(24:40) Starting Points for Global Founders to Connect to the Eco-System in and around Boston
(26:40) Real Life and Digital Meetings – The Best of Two Worlds
(29:55) Fundraising in the United States – 3 Key Success Factors
(33:17) Relationship-building with Investors and Duration of Fundraising in 2022
(31:08) The 3 Do's and Don'ts When Fundraising with US-Based Investors
(44:05) Vision Statement – Pepper Bio
(47:10) The Story Behind Pepper Bio's Foundation
(51:12) Challenges in Drug Development to Improve Success Rates
(55:49) Novel Solutions for Making Sense of Scientific Data
(01:00:15) Pepper Bio's Team
(01:03:30) The Importance of Aligning Vision – Goals – Actions
(01:05:00) Hiring Strategy
(01:05:30) Fundraising at Pepper Bio in 2022
(01:09:10) What is the Best First Step Towards Entrepreneurship?
Podcast Links:
Podcast Community: https://lsg2g.substack.com/
Community Partner: https://linktr.ee/lsg2g
Christian Soschner: https://linktr.ee/soschner
LSG2G Linkedin: https://www.linkedin.com/company/life-science-get2gether
Podcast Episodes: https://pod.link/1493847125
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
What is the best methodology for presenting your Company to investors, industry partners, and public funding organizations?
Here is the answer:
In this episode, Donna LaVoie presents her famous “15-slides-methodology” in great detail.
Donna is a proven strategic communications leader in health and science innovation. She is a trusted advisor on strategic communications issues, especially around complex problems affecting multiple stakeholders. She brings a unique combination of public and investor relations expertise, including product launch experience.
LaVoieHealthScience was launched in 2001 after a corporate career with signature biotech companies leading strategic communications functions during tremendous growth, product and business launches, and international geographic expansion.
As an acknowledged leader in health science communications with public and investor platforms, LaVoieHealthScience is recognized as a top 30 independent healthcare agency in the US. The agency has received more than 35 awards for its client work. It is recognized by INC.5000 Hall of Fame – Fastest Growing Private Companies, Boston Business Journal’s top Massachusetts PR firms, PharmaVOICE 100, and O’Dwyers.
We are talking about:
↪️ Why 15 slides are sufficient in corporate presentations
↪️ Why you should have an Agenda slide
↪️ Why an Appendix is important
↪️ What is Better? Detail or Simplicity?
↪️ The interplay of Problem and Solution
↪️ Why the Team slide matters
↪️ Why you need to adapt the presentation to your audience
↪️ And much, much more
Youtube Video
🕛 Timestamps:
(00:00) Intro
(00:45) Donna LaVoie and LaVoieHealthSciences
(02:35) Content of the Episode
(03:00) Review of #bio2022 in San Diego
(04:04) The 15 Slides Presentation Methodology
(08:42) Why is the 15 Slides Methodology Relevant for Experienced Presenters?
(12:15) Why are you here – What is your ask?
(14:00) Why are conventions important?
(16:05) Should Presenters consider the different cultural backgrounds when preparing for presentations?
(16:51) The Importance of Colours
(19:33) Storytelling, Simplicity, Novelty, and Clarity – The Ingredients of Successful Pitch Decks
(24:00) Industry Dilemma
(24:30) What’s Your Story? – 15 Slides Topics Overview
(27:45) Title Slide
(31:15) Company Snapshot
(32:12) The Agenda Why Creating Anticipation as a Hook Matters in Presentations
.(33:00) Describing the Problem and the Solution – Why it Matters
(37:15) The Market and Target Product Profile
(40:00) Competitive Positioning
(42:20) The Team
(46:45) The Pipeline and Clinical Data
(50:00) Regulatory Strategy
(51:00) Manufacturing Strategy
(52:35) Commercial Strategy
(55:00) Financials
(56:45) Summary of the Presentation
(58:30) How Specific Should Deal terms be in a Pitch Presentation?
(01:01:45) Ending Slide – Cultural and Diversity Considerations
(01:03:00) How Much Time Should Executives Take to Prepare their Corporate Story for Fundraising?
(01:05:00) How LaVoie Health Science Helps Life Science Entrepreneurs and Investors
Podcast Links:
Podcast Community: https://lsg2g.substack.com/
Community Partner: https://linktr.ee/lsg2g
Christian Soschner: https://linktr.ee/soschner
LSG2G Linkedin: https://www.linkedin.com/company/life-science-get2gether
Podcast Episodes: https://pod.link/1493847125
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
Happy Birthday, Inits. Today 20 years ago – July 27, 2002 – Inits – Vienna’s most important high Tech Incubation Program was created.
In this episode, I am talking with Irene Fialka, CEO of Inits. In 20 years, Inits has supported over 300 high-tech #startups with the necessary tools for a successful and sustainable market entry.
Dr. Irene Fialka is CEO of INiTS, Vienna’s University Business Incubator (UBI), supporting entrepreneurs with R&D-based business ideas serving all academic institutions in Vienna. She has a genetics/molecular biology background and has worked with deep-tech startups since 2004.
Under her leadership, INiTS was awarded three times by UBI Globalas, one of the TOP ranked UBIs in the world. INiTS’ startups have proven to be extremely successful in raising funds (12 x the average UBI-supported startup according to UBI Global) and finding strategic partners. She worked with the founders of, e.g., Apeptico, Blue Danube Robotics, Lexogen, Lithoz, Marinomed, mySugr, and many more. Marinomed is the first of over 300 companies that went public in 2019 (IPO on the Vienna Stock exchange).
In collaboration with partners such as Boehringer Ingelheim, Pfizer, and Uniqa, Dr. Fialka and her team launched the HealthHubVienna (healthhubvienna.com) in 2018, an acceleration program for international health startups to drive innovation and change in the healthcare industry in Europe.
In this episode, we are talking about:
Youtube Video
I wish the team of Inits all the best for their birthday celebration. Keep up your great work – it has a huge positive impact on the startup ecosystem in Europe
🕛 Timestamps
(00:00) Kick Off
(03:00) Birthday Wishes
(04:00) When Did Inits Start?
(05:30) From 2002 to 2022 – How Did the Eco-System in Vienna Evolve?
(07:40) Early Days of Life Science in Austria – Intercell in 1997, Alexander von Gabain, Werner Lanthaler, Max Birnstiel
(08:25) What was Inits Starting Point in 2002?
(09:20) Tech Transfer in Austria Early 2000 – The Days of the “Ausseninsitut”
(12:32) Business Models of Academic StartUps and Their Challenges – from 2002 to 2022
(15:20) Impressive KPIs of Inits
(19:00) Companies are About Making Revenues
(21:16) Inits For Academic Startups in 2022
(26:35) Public Funding in Austria
(27:32) How the Campus in St. Marx Developed since 2006 – Vienna Bio Center, Start-Up Labs, Inits.
(29:45) INits Support in 2004
(31:00) Coaching, Mentoring, and Advising for Startups
(32:30) The 3 Major Developments at INITS Since 2002
(38:20) INiTs StartUps In Africa
(43:20) Challenges and Opportunities in the Global StartUp Eco-System
(45:05) StartUp Success Stories from the Inits Universe – MySugr, Shpock, Zoho, Marinomed, Origimm, Lithos, Ecop
(52:05) Consistency between Strategy and Action – Aligning Interests
(55:05) 3 Avoidable Mistakes in Startups
(58:52) Patience and Endurance as Ingredients For Success
(01:00:05) Digital Health – Health Hub Vienna
(01:01:50) Inits Vision for the Coming Two Decades
(01:02:15) Diversity and Female Founders
(01:03:25) Integrating Circular Economy Concepts & Sustainability
(01:04:00) How is the Situation for Female Founders in Europe?
(01:10:00) Diana Project
(01:14:00) Diversity in Corporate Teams – From Startups To ScaleUps, To Investments
(01:17:05) What is the First Step Into Entrepreneurship?
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link